Search This Blog

Friday, February 8, 2019

ImmunoGen sees FY19 revenue $40M-$45M, consensus $64.43M

Sees FY19 operating expenses $265M-$270M. Sees cash and cash equivalents at December 31 $135M-$140M.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)